PPARγ 인산화 변이체를 포함하는 동맥경화 및 혈관재협착 치료 또는 예방용 조성물
    1.
    发明公开
    PPARγ 인산화 변이체를 포함하는 동맥경화 및 혈관재협착 치료 또는 예방용 조성물 有权
    包含PPARGAMMA PHOSPHORYLATION突变体的组合物,用于预防或治疗甲状腺功能亢进和保留

    公开(公告)号:KR1020090100567A

    公开(公告)日:2009-09-24

    申请号:KR1020080025827

    申请日:2008-03-20

    CPC classification number: A61K38/1783 A61K47/6957 C12N15/1138 Y10S514/824

    Abstract: PURPOSE: A composition for preventing or treating atherosclerosis and restenosis, which contains PPARγ phosphorylation mutant is provided to prevent the symptom of restenosis. CONSTITUTION: A composition for preventing or treating atherosclerosis and restenosis comprises a mutant which suppresses phosphorylation at 112th serine of PPARγ amino acid sequence or mutation-inducing material. The mutant is a mutant which 112th serine is substituted with other amino acid residue in the PPARγ amino acid sequence.

    Abstract translation: 目的:提供含有PPARγ磷酸化突变体的预防或治疗动脉粥样硬化和再狭窄的组合物,以预防再狭窄症状。 构成:用于预防或治疗动脉粥样硬化和再狭窄的组合物包含抑制PPARγ氨基酸序列的第112丝氨酸或突变诱导材料的磷酸化的突变体。 该突变体是第112丝氨酸被PPARγ氨基酸序列中的其它氨基酸残基取代的突变体。

    PPARγ 수모화 변이체를 포함하는 동맥경화 및 혈관재협착 치료 또는 예방용 조성물
    2.
    发明公开
    PPARγ 수모화 변이체를 포함하는 동맥경화 및 혈관재협착 치료 또는 예방용 조성물 有权
    包含PPARgamma的组合物; 预防或治疗甲状腺功能亢进和继发的SUMYYLATION突变体

    公开(公告)号:KR1020090092124A

    公开(公告)日:2009-08-31

    申请号:KR1020080017448

    申请日:2008-02-26

    Abstract: A composition for treating and preventing atherosclerosis and restenosis, which contains mutant of PPARgamma(peroxisome proliferator activated receptor gamma) SUMOylation is provided to prevent, relieve and treat stenosis of blood vessel after surgery for atherosclerosis. A composition for preventing and treating restenosis and atherosclerosis comprises matant or mutation inducer in which SUMOylation is suppressed at 107th lysine in the amino acid sequence. The mutant is substituted with arginine from lysine at the 107th amino acid of PPARgamma. The mutation inducer is a material which suppressing enzyme activity of SUMOylation at 107th lysine.

    Abstract translation: 用于治疗和预防动脉粥样硬化和再狭窄的组合物,其包含PPARγ(过氧化物酶体增殖物激活受体γ)SUMO化的突变体,用于预防,缓解和治疗动脉粥样硬化手术后血管狭窄。 用于预防和治疗再狭窄和动脉粥样硬化的组合物包括在氨基酸序列中第107位赖氨酸抑制SUMO化的基因或突变诱导剂。 突变体在PPARγ的第107位氨基酸的赖氨酸被精氨酸取代。 突变诱导剂是抑制第107位赖氨酸的SUMO化的酶活性的物质。

Patent Agency Ranking